

Determination of DNA topoisomerase II activity from L1210 cells — a target for screening antitumor agents

WANG Long-Gui, LIU Xiao-Mei, JI Xiu-Juan (*Institute of Materia Medica,
Chinese Academy of Medical Sciences, Beijing 100050, China*)

ABSTRACT DNA topoisomerase II was isolated from mouse leukemia L1210 cells and the activity was determined by using P4 phage knotted DNA and pBR 322 DNA as the substrates. Based on these results, a method for screening antitumor agents by using DNA topoisomerase II as a target was established.

The experiments showed that DNA topoisomerase II catalyzed pBR 322 DNA breaking and relaxing which were reversible and dependent on ATP. The activity was increased 2–4 times in the presence of ATP $1 \text{ mmol} \cdot \text{L}^{-1}$. In contrast with type II enzyme, the activity of DNA topoisomerase I was completely inhibited in the presence of ATP $1 \text{ mmol} \cdot \text{L}^{-1}$ and had full activity in the absence of ATP. Type II enzyme also showed the unknotting activity by using p4 phage knotted DNA as a substrate. DNA cleavage and relaxing reaction induced by type II enzyme increased 5-fold in the presence of Doxorubicin (Dox) $1 \mu\text{g} \cdot \text{ml}^{-1}$ or daunorubicin (Dau). Etoposide (Eto) and aclarubicin B (Acl B) also stimulated the reaction at $100 \mu\text{g} \cdot \text{ml}^{-1}$. The cleavage reaction resulted from topoisomerase II was inhibited by other agents, such as frankincense extracts, terpenic compounds (BC series).

KEY WORDS DNA untwisting proteins; DNA gyrase; leukemia L1210; antitumor drug screening assays

DNA topoisomerase II is a nuclear enzyme which modifies DNA topology by its ability to break and reseat one or both strands. This enzyme plays very important roles in DNA replication, and other genetic processes⁽¹⁾. DNA topoisomerases I and II are fruitful targets for both antimicrobial and oncologic drug development^(2,3). Many intercalative antitumor drugs have been shown

to induce reversible protein-linked DNA breaks. DNA topoisomerases I and/or II are responsible for this action⁽⁴⁾. A high degree of correlation was found between cytotoxicity and potency of inducing cleavable complex formation *in vivo* and *in vitro*⁽⁵⁾. In the present work an attempt was made to use DNA topoisomerase II as a target for screening antitumor agents.

MATERIALS AND METHODS

Materials Phenylmethyl-sulfonyl fluoride (PMSF), Sigma Chemical Company product, was kindly provided by Professor MA Bender, New York. The working solution in propyl alcohol was made before use. P4 phage DNA was kindly provided by Professor L F Liu, Baltimore, USA. Topoisomerase I was purchased from Promega. ATP was obtained from BDH Chemicals. 1,4-Dithiothreitol (DTT) and proteinase K were products of Merck Company. Sarkosyl, doxorubicin (Dox) and daunorubicin (Dau) were purchased from Sigma Chemical Company and Farmitalia. Aclarubicin B (Acl-B) was a gift from Dr Zhuang Zeng-Hua, Eto was produced by Lian-yun-gang Pharmaceutical Factory. Meisoindigo (Mei), ranuculin (Ran) and terpenic compounds (BC series) were synthesized or extracted by our institute. Acetylshikonin (Ace) was provided by Institute of Botany, the Chinese Academy of Sciences. [³H] TdR ($925 \text{ GBq} \cdot \text{mmol}^{-1} \cdot \text{L}^{-1}$) was purchased from Chinese Academy of Atomic Energy Sciences.

Cells Mouse leukemia L1210 cells were obtained from the DBA/2 mouse 6 or 7 d

Received 1989 Oct 4

Accepted 1990 Nov 2

after transplantation, washed with phosphate buffer solution (PBS) for several times and counted. KB cells were grown in RPMI 1640 medium (Gibco) with penicillin $40 \text{ IU} \cdot \text{ml}^{-1}$, streptomycin $50 \mu\text{g} \cdot \text{ml}^{-1}$ and 10% fetal calf serum, and incubated at 37°C in the presence of 5% CO_2 . The cells were seeded for 24 h before the experiment.

Alkaline Elution The alkaline elution technique for assaying DNA single-strand breaks (SSB) has been described previously⁽⁶⁾. Briefly, 2.5×10^5 – 5.0×10^5 of KB cells were labeled with [^3H]TdR for 16 h. The medium containing radioactivity was removed and fresh medium was added to the culture and the cells were incubated for another 12 h. The labeled cells were treated with Eto, Dox, Mei or Ran for 1 h. Washed twice with ice-cold PBS (pH 7.4), harvested by rubber policeman, loaded on polyvinyl chloride filter ($1.2 \mu\text{m}$) and lysed with a solution of 2% SDS, EDTA $20 \text{ mmol} \cdot \text{L}^{-1}$ (pH 10.0). The DNA was eluted from the filter with NaOH at pH 12.0. The rate of elution was $1.5 \text{ ml} \cdot \text{h}^{-1}$ with a fraction interval of 1 h. And a total elution time of 10 h.

Extraction of topoisomerase II from mouse leukemia L1210 cells The mouse leukemia L1210 cells were drawn from mouse 6 or 7 d after transplantation and washed twice with ice-cold PBS. 1×10^8 Cells were suspended in 10 ml of TMN (Tris $10 \text{ mmol} \cdot \text{L}^{-1}$, pH 7.5, MgCl_2 $1.5 \text{ mmol} \cdot \text{L}^{-1}$ and NaCl $10 \text{ mmol} \cdot \text{L}^{-1}$) and allowed to set at 0°C for 10 min. One ml of 10% Sarkosyl was added to the cell suspension and the mixture gently triturated and finally left at 0°C for 15 min. The cells were then centrifuged at $3000 \times g$ for 10 min, and the pellet was resuspended in 2 ml of ice-cold buffer A (Tris $50 \text{ mmol} \cdot \text{L}^{-1}$, pH 7.5, KCl $25 \text{ mmol} \cdot \text{L}^{-1}$, CaCl_2 $1 \text{ mmol} \cdot \text{L}^{-1}$, MgCl_2 $3 \text{ mmol} \cdot \text{L}^{-1}$, sucrose $0.25 \text{ mol} \cdot \text{L}^{-1}$), and fresh PMSF in propanol was added to final concentration of $1 \text{ mmol} \cdot \text{L}^{-1}$ and kept in ice for 2 min, the 0.6 ml of buffer B (buffer A with $0.6 \text{ mol} \cdot \text{L}^{-1}$

sucrose) and sedimented at $5000 \times g$ for 10 min. The pellet was resuspended in 2 ml buffer C (buffer A without CaCl_2 and with MgCl_2 $5 \text{ mmol} \cdot \text{L}^{-1}$), centrifuged at $5000 \times g$ for 10 min and finally the pellet was resuspended in 0.15 ml of buffer D (same as buffer C but without sucrose), 15 μl of EDTA $0.2 \text{ mol} \cdot \text{L}^{-1}$ (pH 8.0) and 0.33 ml of buffer E [Tris $80 \text{ mmol} \cdot \text{L}^{-1}$, pH 7.5, EDTA $2 \text{ mmol} \cdot \text{L}^{-1}$, DTT $1 \text{ mmol} \cdot \text{L}^{-1}$, NaCl $0.53 \text{ mol} \cdot \text{L}^{-1}$, and 20% glycerol, (vol \cdot vol $^{-1}$)]. This mixture was gently triturated, left at 0°C for 30 min, and centrifuged at $40000 \times g$ for 20 min. The protein concentration of the supernatant containing topoisomerase II was determined by colorimetric method⁽⁷⁾. The enzyme solution was diluted with an equal volume of glycerol, and BSA and PMSF were added to get final concentrations of $1 \text{ mg} \cdot \text{ml}^{-1}$ and $0.5 \text{ mmol} \cdot \text{L}^{-1}$, respectively. The enzyme is stable at -20°C for 3 wk.

Cleavage of plasmid pBR 322 DNA Supercoiled pBR 322 DNA was isolated according to procedures of "large scale preparation of plasmid DNA"⁽⁸⁾ and treated with $200 \mu\text{g} \cdot \text{ml}^{-1}$ of RNase at 37°C for 1 h. Three bands (form I : supercoiled; form II : nicked circular and form III : linear) should appear on 0.8% agarose gel after electrophoresis. A 20- μl assay contained 5 μl of cleavage buffer (Tris $200 \text{ mmol} \cdot \text{L}^{-1}$, pH 7.5, KCl $340 \text{ mmol} \cdot \text{L}^{-1}$, MgCl_2 $40 \text{ mmol} \cdot \text{L}^{-1}$, DTT $20 \text{ mmol} \cdot \text{L}^{-1}$, BSA $120 \mu\text{g} \cdot \text{ml}^{-1}$ and ATP $4 \text{ mmol} \cdot \text{L}^{-1}$), 1 μg of pBR 322 DNA, and various amounts of topoisomerase II. After incubation at 37°C for 30 min, the reaction was terminated by adding 2 μl of 10% SDS and 2 μl of proteinase K ($10 \text{ mg} \cdot \text{ml}^{-1}$). The mixture was then incubated at 37°C for another 30 min. Two μl of loading buffer (bromophenol blue 0.42%, xylene cyanol 0.42% and glycerol 50% in H_2O) were added, the DNA was subjected to electrophoresis on 0.8% agarose gel at 80 V for 2 h, and the gel was stained with $1 \mu\text{g} \cdot \text{ml}^{-1}$ of EB solution for 30 min.

Effects of antitumor agents on the enzyme activity The cleavage reaction induced by DNA topoisomerase II can be affected by some antitumor agents in 2 ways, ie, stimulation and inhibition. For the former 0.2 U of the enzyme in the cleavage reaction was used in which supercoiled pBR 322 DNA (form I) did not become nicked in circles (form II) or linear (form III) significantly. For the latter 1 U of the enzyme was used so that the form I DNA band disappear completely in the absence of drug. Then the reaction was performed as above except that an antitumor agent was added to the reaction system.

RESULTS

Catalytic activities of topoisomerases

The catalytic activity of topoisomerase II was estimated by cleavage reaction. One μg of pBR 322 DNA was incubated with 0.1, 0.3 and 0.5 μg of the proteins extracted from L1210 cells in the reaction mixtures for 30 min as described above and 1 U of the enzyme is defined as the amount of proteins which caused 1 μg of supercoiled pBR 322 DNA to become form II or form III DNA at 37°C in 30 min. As shown in Fig 1a (lane B to D), the catalytic reaction showed a function of the amount of enzyme proteins in the presence of ATP 1 $\text{mmol} \cdot \text{L}^{-1}$. About 0.5 μg of the proteins were needed to complete the cleavage reaction. The specific activity of the enzyme was found to be about 2000 $\text{U} \cdot \text{mg}^{-1}$. However, the activity decreased (1.5 μg of the enzyme proteins were needed for full reaction) when the reaction was performed in the absence of ATP. In contrast with topoisomerase II, the activity of topoisomerase I was inhibited by ATP 1 $\text{mmol} \cdot \text{L}^{-1}$ (Fig 1, lane I to J) and the enzyme showed a full activity in the absence of ATP (Fig 1b, lane K to L).

Effects of NaCl on topoisomerase II activity One of the characters of topoisomerase II is that the cleavage of supercoiled DNA by the enzyme can be inhibited by high concentrations of NaCl. In our

reaction system pBR 322 DNA 2.5 μg , enzyme proteins 2.5 U and different amount of NaCl were added to cleavage buffer to a final volume of 50 μl . Fig 2 indicated that the inhibition of NaCl on catalytic activity of topoisomerase II was a function of the concentration of the salt. Addition of high concentrations of NaCl (0.25 $\text{mol} \cdot \text{L}^{-1}$, lane E and 0.5 $\text{mol} \cdot \text{L}^{-1}$, lane F) to the reaction mixture the cleavage was completely blocked. This result is consistent with the previous report⁽⁹⁾.




Fig 1. Cleavage and relaxing of pBR 322 DNA by topoisomerases with or without ATP. Lane A: pBR 322 DNA only; lane B to D: DNA and 0.1, 0.3, 0.5 μg of the extracts with ATP 1 $\text{mmol} \cdot \text{L}^{-1}$; lane E to G: same as the "B to D", but without ATP; lane H: DNA only; lane I to J: DNA and 0.5, 1.0 U topoisomerase I with ATP 1 $\text{mmol} \cdot \text{L}^{-1}$; lane K to L: same as the "I to J", but without ATP.

Reversibility of the topoisomerase II cleavage reaction Cleavage reaction induced by topoisomerase II is reversible. After completion of the reaction, the mixture was set on ice bath or high concentration of NaCl was added to the mixture (final concentration of NaCl 0.5 $\text{mol} \cdot \text{L}^{-1}$) and incubated at 37°C for 30 min. As shown in Fig 3, the cleavage reaction was reversed by decreasing temperature from 37 °C to 0 °C (lane C) or high concentra-




Fig 2. Inhibition of NaCl on cleavage of DNA by mouse leukemia L1210 cell topoisomerase II. A reaction mixture (30 μ l) contained 7.5 μ l CB, 3.0 μ g pBR 322 DNA, 3 U topoisomerase II and different concentrations of NaCl. Lane A is the control (no enzyme). Final NaCl concentrations in lane B to G were 0, 500, 250, 125, 62.5 and 31 $\text{mmol} \cdot \text{L}^{-1}$, respectively.




Fig 3. Reversible cleavage of pBR 322 DNA by mouse leukemia L1210 cell topoisomerase II. A 30- μ l assay contained the same buffer as above, 3.0 μ g pBR 322 DNA and 3.0 U DNA topoisomerase II. Lane A (without the enzyme) and B (with the enzyme) are the controls. Lane C: after incubation at 37°C for 30 min, the reaction mixture was kept on ice-bath for 30 min. Lane D: 500 $\text{mmol} \cdot \text{L}^{-1}$ of NaCl was added to the mixture and incubated at 37°C for another 30 min. The reactions both in lane C and D were terminated.

tion of sodium chloride (lane D) compared with control (lane A). This result is also in agreement with the previous report⁽⁹⁾.

Unknotting activity The unknotting of knotted P4 phage DNA is shown in Fig 4. As the reaction proceeds, the faster migrating smear of multiple knotted DNA was converted to the slower moving heavy band of unknotted circular molecules. This reaction was inhibited by ADM (comparing lane C with lane D).




Fig 4. Assay for unknotting activity of topoisomerase II from L1210 cells. Reactions (20 μ l each) were conducted under the same conditions as those described for the cleavage assay except that P4 knotted DNA (1 μ g) was used. Lane A: P4 knotted DNA only; lane B, C: P4 DNA with 1.5 and 3.0 μ g enzyme extracts; lane D: P4 DNA with 3 μ g enzyme extracts and 10 μ g Dox.

Effects of antitumor agents on topoisomerase II activity

1 Stimulation of DNA cleavage After incubation of pBR 322 DNA 1 μ g with 0.2 U of topoisomerase II extracted from mouse leukemia L1210 cells in the presence (lane E to P in Fig 5A) or absence (Fig 5A, lane B) of Eto, Dox, Dau and Acl-B 1, 10, and 100 $\mu\text{g} \cdot \text{ml}^{-1}$, the reaction products were treated with SDS, proteinase K and then electrophorised on 0.8 % agarose gel. The presence of Dox and Dau 1 $\mu\text{g} \cdot \text{ml}^{-1}$ reproducibly stimulated DNA cleavage by 5-fold in the presence of the enzyme (only 0.2 U of the enzyme was needed for complete cleavage). Eto and Acl-B also enhanced the cleavage ability of topoisomerase II but with higher concentrations in our experimental conditions (Tab 1). The high concentrations of Dox and Dau (100 $\mu\text{g} \cdot \text{ml}^{-1}$) induced alteration of mobility of the DNA on the agarose gel electrophoresis. This might result from the intercalation of the drugs to DNA. However, the stimulations of DNA

cleavage by topoisomerase II in the presence of Mei, Ace, Ara-c, and Ran were not seen (Fig 5B).



Fig 5. Effect of antitumor drugs on pBR 322 DNA cleavage reaction by topoisomerase II. A: Lane A: DNA only; lane B to D: DNA with the enzyme (0.1, 0.3 and 0.5 μg); lane E to G: 0.2 U enzyme and treatment with 1, 10, 100 $\mu\text{g} \cdot \text{ml}^{-1}$ of Eto; lane H to J: 100, 10 and 1 $\mu\text{g} \cdot \text{ml}^{-1}$ of Dox; lane K to M: 100, 10 and 1 $\mu\text{g} \cdot \text{ml}^{-1}$ of Dau; lane N to P: 100, 10 and 1 $\mu\text{g} \cdot \text{ml}^{-1}$ of Acl-B. B: Lane A: DNA only; lane B: DNA with 0.2 U enzyme; lane C: 10 $\mu\text{g} \cdot \text{ml}^{-1}$ Dox; lane D to F: 100, 10 and 1 $\mu\text{g} \cdot \text{ml}^{-1}$ of Mei; lane G to I: 100, 10 and 1 $\mu\text{g} \cdot \text{ml}^{-1}$ of Ace; lane J to L: 100, 10 and 1 $\mu\text{g} \cdot \text{ml}^{-1}$ of Ran; lane M to O: 100, 10 and 1 $\mu\text{g} \cdot \text{ml}^{-1}$ of Arc-C.

2 Inhibition on the catalytic activity

The cleavage reaction catalysed by topoisomerase II can be inhibited by some chemicals. As shown in Fig 6 and Tab 1, when 2.5 μg of pBR 322 DNA reacted with 2.5 U of topoisomerase II in the absence of drugs band I completely disappeared. The reactions were stopped when terpenic compound BC-1, BC-4, BC-9 100 μmol or BC-M 200 μmol were added to the reaction system. These agents also showed cytotoxicity (data not shown).

DNA single strand breaks induced by antitumor agents DNA single strand breaks (SSB) induced by antitumor agents was

Tab 1. Stimulations of Eto, Dox, Dau and Acl-B and inhibitions of BC series on pBR 322 DNA cleavage reaction catalyzed by topoisomerase II. -: no activity; +: half activity and ++: full activity.

Topoisomerase II (units)	Drug	Stimulation or inhibition activity			
		1.0	10.0	100.0	200.0
0.2	Eto, $\mu\text{g} \cdot \text{ml}^{-1}$	-	+	++	
	Dox, $\mu\text{g} \cdot \text{ml}^{-1}$	++	++	++	
	Dau, $\mu\text{g} \cdot \text{ml}^{-1}$	++	++	++	
	Acl-B, $\mu\text{g} \cdot \text{ml}^{-1}$	-	-	+	
	Arc-C, $\mu\text{g} \cdot \text{ml}^{-1}$	-	-	-	
	Ace, $\mu\text{g} \cdot \text{ml}^{-1}$	-	-	-	
	M-GAG, $\mu\text{g} \cdot \text{ml}^{-1}$	-	-	-	
	CMT, $\mu\text{mol} \cdot \text{L}^{-1}$	-	-	-	
	Mei, $\mu\text{mol} \cdot \text{L}^{-1}$	-	-	-	
	Ran, $\mu\text{mol} \cdot \text{L}^{-1}$	-	-	-	
VCR, $\mu\text{mol} \cdot \text{L}^{-1}$	-	-	-		
1.0	BC-1, $\mu\text{mol} \cdot \text{L}^{-1}$	-	+	++	
	BC-3, $\mu\text{mol} \cdot \text{L}^{-1}$			-	
	BC-4, $\mu\text{mol} \cdot \text{L}^{-1}$			-	
	BC-4, $\mu\text{mol} \cdot \text{L}^{-1}$			+	
	BC-6, $\mu\text{mol} \cdot \text{L}^{-1}$			-	
	BC-8, $\mu\text{mol} \cdot \text{L}^{-1}$			-	
	BC-9, $\mu\text{mol} \cdot \text{L}^{-1}$	-	+	++	
	BC-M, $\mu\text{mol} \cdot \text{L}^{-1}$			-	+



Fig 6. Inhibition of topoisomerase II activity by antitumor agents. Lane A: DNA only; lane B: DNA with 1 U of the enzyme; lane C: treated with 10 $\mu\text{g} \cdot \text{ml}^{-1}$ of Dox; lane D to F: treated with 1, 10, 100 $\mu\text{mol} \cdot \text{L}^{-1}$ of BC-1; lane G to I: treated with 1, 10, 100 $\mu\text{mol} \cdot \text{L}^{-1}$ of BC-1; lane J to K: treated with 200 and 100 $\mu\text{mol} \cdot \text{L}^{-1}$ of BC-4M.

estimated by alkaline elution technique. As shown in Fig 7 SSB in KB cells were observed after the treatment with Eto and Dox, and the numbers of breaks were increased with increasing drug concentrations. At higher concentrations, Eto

produced greater numbers of SSB, although the curves tended to level off, as if approaching saturation (Fig 7). But DNA single strand breaks were not obtained when KB cells were exposed to Ran and Mei under the same experimental conditions (Fig 7).




Fig 7. Analysis of DNA single strand breaks induced by antitumor drugs in KB cells by means of alkaline elution. The cells were exposed to 10 and 30 $\mu\text{g} \cdot \text{ml}^{-1}$ of Eto, Dox, or 10 to 30 $\mu\text{mol} \cdot \text{L}^{-1}$ of Ran and Mei for 1 h, washed twice with cold PBS and eluted with NaOH solution (pH 12.00). (○) : control; (●) : 10 $\mu\text{g} \cdot \text{ml}^{-1}$ or $\mu\text{mol} \cdot \text{L}^{-1}$; (×) : 30 $\mu\text{g} \cdot \text{ml}^{-1}$ or $\mu\text{mol} \cdot \text{L}^{-1}$.

DISCUSSION

In recent years, many methods have been reported for the isolation and purification of topoisomerase II^(10,11), but most of them are complicated and time-consuming. In the present study, we utilized the procedures reported by Sullivan *et al*⁽¹²⁾, with some modifications. The major amendment was that at the last step of centrifugation higher speed was used to remove nucleic acid which may interfere with the cleavage reaction. The procedures for extraction of topoisomerase II re-

ported here have an advantage of easiness and time-saving. All extractions can be finished in a few hours. The characters of topoisomerase II we detected, such as unknotting activity, cleavage reaction, effects of ATP and NaCl on cleavage reaction and the reversibility of the cleavage reaction by topoisomerase II, are consistent with the previous reports^(9,13,14). The findings that cleavage reaction catalyzed by topoisomerase I can be inhibited by ATP 1 $\text{mmol} \cdot \text{L}^{-1}$ indicate that interference of topoisomerase I which may occur in the extracts can be removed by adding ATP 1 $\text{mmol} \cdot \text{L}^{-1}$ to the reaction system.

Some workers^(4,15) reported the effects of DNA intercalating agents on topoisomerase II induced DNA SSB and breakage-reunion. In our experiments, stimulations of Dox, Dau, Eto and Acl-B and inhibitions of BC-1, BC-4, BC-9 and BC-M on DNA cleavage reaction by topoisomerase II were observed. SSB induced by Eto and Dox was also obtained by means of alkaline elution technique. Nevertheless the stimulations of cleavage reaction resulted from Mei, Ace, Ran and Ara-c and DNA SSB induced by Ran and Mei in the presence of DNA topoisomerase II have not been found. There is a good correlation between the stimulation of DNA cleavage by topoisomerase II and formation of DNA SSB in the presence of some antitumor agents.

A number of concepts regarding topoisomerases as drug targets are becoming better defined. Lock *et al*^(2,3) suggested that for inhibitors of both topoisomerases, a major effort must be made to elucidate the physicochemical nature of the drug-enzyme DNA interaction. Synthetic and natural product screening efforts will hopefully generate new inhibitors for both enzymes which, upon systematic analysis, may lead to a unifying model to account for drug effects at the molecular level. Based on this idea, we estab-

lished a method for screening anticancer drugs by using topoisomerase II as a target. Some natural products have been screened by using the method we reported here and interesting results have been obtained. However, as with the development of other drugs there are limitations for using this method to screen antitumor drugs. In fact this method is only suitable to the agents which may interfere with topoisomerase II.

REFERENCES

- 1 Liu FL, Miller KG. Eukaryotic DNA topoisomerases: Two forms of type I DNA topoisomerases from HeLa cell nuclei. *Proc Natl Acad Sci USA* 1981; 78 : 3487
- 2 Lock RB, Ross WE. DNA topoisomerases in cancer therapy. *Anti-Cancer Drug Design* 1987; 2 : 151
- 3 Ross WE, Macdonald TL, Hertzberg, RP. DNA topoisomerases as targets for new drug development. *Proc Am Assoc Cancer Res* 1988; 29 : 534
- 4 Tewey KM, Chen GL, Nelson EM, Liu LF. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. *J Biol Chem* 1984; 259 : 9182
- 5 Rowe TC, Chen GL, Hsiang YH, Liu LF. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. *Cancer Res* 1986; 46 : 2021
- 6 Wang LG, Zeng H. DNA-protein, DNA interstrand cross-links induced by camphoramine chloroacetic platinum *in vitro*. *Acta Pharmacol Sin* 1989; 10 : 261
- 7 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. *Anal Biochem* 1976; 72 : 248
- 8 Maniatis T, Fritsch EF, Sambrook J. *Molecular cloning, a laboratory manual*. NY: Cold Spring Harbor, 1982; 86
- 9 Liu LF, Rowe TC, Yang L, Tewey KM, Chen GL. Cleavage of DNA by Mammalian DNA Topoisomerase II. *J Biol Chem* 1983;

258 : 15365

- 10 Miller KG, Liu LF, Englund PT. A Homogeneous Type II DNA Topoisomerase from HeLa Cell Nuclei. *J Biol Chem* 1981; 256 : 9334
- 11 Halligan BD, Edwards KA, Liu LF. Purification and characterization of a type II DNA topoisomerase from bovine calf thymus. *J Biol Chem* 1985; 260 : 2475
- 12 Sullivan DM, Glisson BS, Hodges PK, Smallwood-kentro S, Ross WE. Proliferation dependence of topoisomerase II mediated drug action. *Biochemistry* 1986; 25 : 2248
- 13 Goto T, Laipis P, Wang JC. The purification and characterization of DNA topoisomerases I and II of the yeast *saccharomyces cerevisiae*. *J Biol Chem* 1984; 259 : 10422
- 14 Osheroff N. Biochemical basis for the interactions of type I and type II topoisomerases with DNA. *Pharmacol Ther* 1989; 41 : 233
- 15 Pommier Y, Schwartz RE, Kohn KW, Zwelling LA. Formation and rejoining of deoxyribonucleic acid double-strand breaks induced in isolated cell nuclei by antineoplastic intercalating agents. *Biochemistry* 1984; 23 : 3194

细胞 L1210 拓扑异构酶 II 活性的测定—筛选抗癌药的靶点

王龙贵、刘晓梅、籍秀娟(中国医学科学院药物研究所, 北京 100050, 中国)

摘要 以小鼠 L1210 白血病细胞为材料提取了 DNA 拓扑异构酶 II, 并以 P-4 打结 DNA 和 pBR 322 DNA 为底物测定了该酶活性, 在此基础上初步建立了以拓扑异构酶 II 为靶点筛选抗癌药的方法. 实验表明拓扑异构酶 II 能使 pBR 322 DNA 断裂和解旋, 该反应是可逆的, ATP 依赖性的. 在 ATP 1 mmol · L⁻¹ 时, 酶活性可增加 2-4 倍. 相反 ATP 1 mmol · L⁻¹ 能抑制拓扑异构酶 I 的活性. 实验还表明, 1 μg · ml⁻¹ 阿霉素、柔红霉素能使拓扑异构酶 II 催化的 DNA 断裂反应增强 5 倍. 足叶草甙、阿克拉霉素 B 在 100 μg · ml⁻¹ 时也有同样作用. 相反, 植物提取物 BC 系列对该酶介导的 DNA 断裂则有抑制作用.

关键词 DNA 脱氧核糖核酸非扭曲蛋白类; 脱氧核糖核酸解旋酶类; 白血病 L1210; 抗肿瘤药; 筛选试验